• All Rooms
• Room 1
• Room 2
• Room 3
• Room 4
• Room 1+2

March 27 (Thursday)

[JS01] MOU Session - Adult Acute Lymphoblastic Leukemia in Asia Room 1

• March 27 (Thu), 09:00-10:15
• TBA
• 09:00-09:15 Opportunities and challenges in managing adult ALL in Vietnam Han Viet Trung (Bach Mai Hospital, Vietnam) 09:15-09:30 Adult ALL in Armenia Armine Farmazyan (Hematology center after Prof. Yeolyan, Armenia) 09:30-09:45 Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand Weerapat Owattanapanich (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand) 09:45-10:00 Adult ALL in Korea Ik Chan Song (Chungnam National University College of Medicine, Korea) 10:00-10:15 Discussion

[SS01] Improving outcomes in challenging Pediatric Leukemia Room 2

• March 27 (Thu), 09:00-10:15
• TBA
• 09:00-09:25 Diagnosis and treatment of Ph-like ALL in children and young adults Thai Hoa Tran (Université de Montréal, Canada) 09:25-09:50 Advances in the genetics of down syndrome-related myeloid leukemias Etsuro Ito (Hirosaki University Graduate School of Medicine, Japan) 09:50-10:15 Towards improving outcomes for high risk pediatric acute myeloid leukemia Todd Cooper (Seattle Children’s Hospital, USA)

[SS02] Overcoming the resistance mechanisms of Multiple Myeloma Room 3

• March 27 (Thu), 09:00-10:15
• TBA
• 09:00-09:25 Immune therapy and the bone marrow microenvironment in multiple myeloma Hearn Jay Cho (Icahn School of Medicine at Mount Sinai, USA) 09:25-09:50 Mechanisms of antigen escape after T-cell based immunotherapies Paola Neri (University of Calgary, Canada) 09:50-10:15 Cellular immunotherapy platforms in multiple myeloma Sung-Hoon Jung (Chonnam National University Medical School, Korea)

[ES01] Understanding the fundamentals of Myelodysplastic Syndrome KOR Room 4

• March 27 (Thu), 09:00-10:15
• TBA
• 09:00-09:25 Tracing the changes: MDS risk stratification Seo-Yeon Ahn (Chonnam National University Medical School, Korea) 09:25-09:50 Managing MDS with HMAs following the AZA-001 trial Silvia Park (College of Medicine, The Catholic University of Korea, Korea) 09:50-10:15 Approved MDS treatments beyond HMAs Junshik Hong (Seoul National University College of Medicine, Korea)

[PL01] Plenary Lecture 01 Room 1+2

• March 27 (Thu), 10:30-11:15
• TBA
• 10:30-11:15 Myeloproliferative Neoplasms: 2025 update Ayalew Tefferi (Mayo Clinic, USA)

[PS01] Presidential Symposium 01 Room 1+2

• March 27 (Thu), 11:15-12:00
• TBA
• 11:15-12:00 CAR T-cell therapy for Lymphomas: Current and future trends Sattva S Neelapu (The University of Texas MD Anderson Cancer Center, USA)

[JS02] EHA-KSH: Acute Myeloid Leukemia - Research and practice Room 1

• March 27 (Thu), 15:25-16:40
• TBA
• 15:25-15:40 Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC) Brian Huntly (University of Cambridge, UK) 15:40-15:55 Treatment of AML in Korea June-Won Cheong (Yonsei University College of Medicine, Korea) 15:55-16:10 Genetics guiding treatment in AML Hartmut Döhner (Ulm University Hospital, Germany) 16:10-16:25 The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study Jae-Sook Ahn (Chonnam National University Medical School, Korea) 16:25-16:40 Discussion

[SS03] Updates in cancer-associated Venous Thromboembolism Room 2

• March 27 (Thu), 15:25-16:40
• TBA
• 15:25-15:50 How to decide and treat when DOAC should not be standard treatment Jeffrey I. Weitz (McMaster University, Canada) 15:50-16:15 Managing patients with cancer associated venous thromboembolism Robert D. McBane II (Mayo College of Medicine, USA) 16:15-16:40 Risk assessment and thromboprophylaxis for cancer-associated VTE Ingrid Pabinger-Fasching (Medical University of Vienna, Austria)

[SS04] Advancements in Peripheral T-cell Lymphoma: From biological insights to innovative treatments Room 3

• March 27 (Thu), 15:25-16:40
• TBA
• 15:25-15:50 Peripheral T-cell lymphoma: From biology to practice Owen A O'Connor (University of Virginia Comprehensive Cancer Center, USA) 15:50-16:15 Recent updates and future in the management of R/R PTCL Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) 16:15-16:40 The development of new agents in T-cell lymphoma Pier Luigi Zinzani (Università di Bologna, Italy)

[ES02] Basic understanding and application of Artificial Intelligence KOR Room 4

• March 27 (Thu), 15:25-16:40
• TBA
• 15:25-15:50 AI everywhere Auk Kim (Department of Computer Science and Engineering, Kangwon National University, Korea) 15:50-16:15 Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation Sang-Hyun Hwang (University of Ulsan College of Medicine, Korea) 16:15-16:40 Generative AI use case for medical research: HRS (Healthcare data research suite) Soo-Yong Shin (Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea)

[SS05] Red blood cells in Myeloproliferative Neoplasm Room 1

• March 27 (Thu), 16:55-18:10
• TBA
• 16:55-17:20 Iron metabolism in JAK2-mutant myeloproliferative neoplasm Radek C. Skoda (Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, USA) 17:20-17:45 Hepcidin in the pathophysiology of and as treatment for polycythemia vera Yelena Z. Ginzburg (Icahn School of Medicine at Mount Sinai, USA) 17:45-18:10 Anemia and JAK inhibitors Jean-Jaques Kiladjian (Saint-Louis Hospital, France)

[SS06] Advances and challenges in Histiocytic diseases: A comprehensive update Room 2

• March 27 (Thu), 16:55-18:10
• TBA
• 16:55-17:20 Innovations in HLH therapy: Emapalumab in clinical practice Carl Allen (Baylor College of Medicine, USA) 17:20-17:45 Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies Oussama Abla (The Hospital for Sick Children, Canada) 17:45-18:10 From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes Melissa Hines (St. Jude Children’s Research Hospital , USA)

[SS07] Breaking new ground in Acute Myeloid Leukemia Room 3

• March 27 (Thu), 16:55-18:10
• TBA
• 16:55-17:20 Understanding and overcoming resistance in AML: Targeted therapy barriers Catherine Smith (University of California San Francisco, USA) 17:20-17:45 Exploring immune checkpoint targets beyond PD-1 and PD-L1 in AML Tae Kon Kim (Vanderbilt University Medical Center, USA) 17:45-18:10 Implementing a functional precision medicine for AML patients Mika Kontro (Helsinki University Hospital, Finland)

[ES03] Turning ideas into successful Clinical Trial: A practical approach KOR Room 4

• March 27 (Thu), 16:55-18:10
• TBA
• 16:55-17:20 Crafting a successful investigator-initiated study proposal: Key elements and strategies Young Woo Jeon (College of Medicine, The Catholic University of Korea, Korea) 17:20-17:45 Current Trends of Big Data Research Using the Korean National Health Information Database Kyung-Do Han (Department of Statistics and Actuarial Science, Soongsil University, Korea) 17:45-18:10 Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting Jeong-Ok Lee (Seoul National University College of Medicine, Korea)